Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

837 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma.
McCrury M, Swafford K, Shuttleworth SL, Mehdi SH, Acharya B, Saha D, Naceanceno K, Byrum SD, Storey AJ, Xu YZ, Doshier C, Patel V, Post GR, De Loose A, Rodriguez A, Shultz LD, Zhan F, Yoon D, Frett B, Kendrick S. McCrury M, et al. Among authors: zhan f. Mol Cancer Ther. 2024 Mar 4;23(3):316-329. doi: 10.1158/1535-7163.MCT-23-0299. Mol Cancer Ther. 2024. PMID: 37816504
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD Jr, Barlogie B, Yaccoby S, Afar DE. van Rhee F, et al. Among authors: zhan f. Mol Cancer Ther. 2009 Sep;8(9):2616-24. doi: 10.1158/1535-7163.MCT-09-0483. Epub 2009 Sep 1. Mol Cancer Ther. 2009. PMID: 19723891 Free PMC article. Clinical Trial.
PHF19 inhibition as a therapeutic target in multiple myeloma.
Schinke CD, Bird JT, Qu P, Yaccoby S, Lyzogubov VV, Shelton R, Ling W, Boyle EM, Deshpande S, Byrum SD, Washam C, Mackintosh S, Stephens O, Thanendrarajan S, Zangari M, Shaughnessy J Jr, Zhan F, Barlogie B, van Rhee F, Walker BA. Schinke CD, et al. Among authors: zhan f. Curr Res Transl Med. 2021 Jul;69(3):103290. doi: 10.1016/j.retram.2021.103290. Epub 2021 Apr 22. Curr Res Transl Med. 2021. PMID: 33894670 Free PMC article.
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD Jr, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M. Mohan M, et al. Among authors: zhan f. Cancer. 2023 Aug 15;129(16):2491-2498. doi: 10.1002/cncr.34895. Epub 2023 Jun 6. Cancer. 2023. PMID: 37282609
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.
Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD Jr, Zhan F. Cheng Y, et al. Among authors: zhan f. Cell Rep Med. 2023 Oct 17;4(10):101214. doi: 10.1016/j.xcrm.2023.101214. Epub 2023 Oct 3. Cell Rep Med. 2023. PMID: 37794587 Free PMC article.
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J Jr, Pecorelli S. Santin AD, et al. Among authors: zhan f. Int J Cancer. 2004 Oct 20;112(1):14-25. doi: 10.1002/ijc.20408. Int J Cancer. 2004. PMID: 15305371 Free article.
837 results